Physician profile
Patrick Skarote
NPI 1598745903
$3,425.13
in general payments reported to CMS, 2019-2025
28 companies · $423 in 2025
The $423 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $232 · 2021: $431 · 2022: $755 · 2023: $856 · 2024: $332 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $996.28 | 2021-2025 | |
| Abbvie INC. | $438.28 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Evofem Biosciences, INC. | $227.35 | 2021-2022 | |
| Hologic Sales and Service, LLC | $174.96 | 2019-2024 | Acessa Provu System, Thinprep 2000 Processor, Coolseal Generator |
| Bayer Healthcare Pharmaceuticals INC. | $150.31 | 2022-2025 | |
| Therapeuticsmd, INC. | $129.50 | 2019-2022 | |
| Ethicon US, LLC | $126.54 | 2019-2020 | |
| Exeltis, USA INC. | $120.92 | 2024-2025 | Slynd |
| Agile Therapeutics, INC. | $113.80 | 2022-2023 | Twirla |
| Myovant Sciences INC. | $106.79 | 2021-2022 | |
| Lupin INC. | $93.02 | 2019-2020 | |
| Millicent US INC | $81.14 | 2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $74.55 | 2020-2022 | |
| Astellas Pharma US INC | $59.63 | 2023-2025 | Veozah |
| Meditrina | $59.49 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien Lp | $58.22 | 2019 | |
| Virtus Pharmaceuticals LLC | $55.72 | 2021-2022 | |
| Pfizer INC. | $53.91 | 2023-2024 | |
| Avion Pharmaceuticals | $46.93 | 2021-2022 | |
| Roche Diagnostics Corporation | $44.59 | 2019 | |
| Sumitomo Pharma America, INC. | $41.81 | 2024-2025 | Myfembree |
| Myriad Women'S Health, INC. | $39.45 | 2023 | Myrisk |
| Mylan Pharmaceuticals INC. | $33.67 | 2022 | |
| Dilon Technologies, INC. | $29.41 | 2025 | Hemoblast Bellows |
| Medtronic, INC. | $23.50 | 2023 | Sonicision |
| Vertical Pharmaceuticals, LLC | $15.89 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.16 | 2019 | |
| Amgen INC. | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Skarote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.